Views & Analysis Tunnah’s musings: Rare diseases hold key to future of drug d... The lessons that can be learned for the future of drug development from the collaboration and innovation in this space.
Views & Analysis Rethinking rare diseases: treat the whole patient CRDN wants to break down barriers in communication between rare disease patients, HCPs and industry.
News In shock move, EU panel rejects Alzheimer's drug Leqembi The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Sales & Marketing Sponsored How doctors are interacting with content in 10 data trends It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.